About Voyager Therapeutics Inc.

Voyager Therapeutics Inc., founded in 2013, has established expertise in developing gene therapies for neurological diseases using advanced AAV vector technologies. The company has built capabilities in vector engineering, manufacturing, and clinical development for complex neurological indications. VYGR stock price reflects both the potential of gene therapy for neurological diseases and the inherent risks of this challenging therapeutic area.

Led by CEO Andre Turenne, Voyager has focused on advancing its gene therapy platform while building strategic partnerships and manufacturing capabilities. The management team combines gene therapy expertise with neurological disease development experience. Leadership's strategic approach to addressing severe neurological conditions through innovative gene therapy has been important for advancing programs and influencing VYGR stock price trajectory.

Voyager operates by developing AAV-based gene therapies for neurological diseases including Huntington's disease, amyotrophic lateral sclerosis (ALS), and other conditions affecting the central nervous system. The company's platform focuses on delivering therapeutic genes directly to affected brain regions. With neurological diseases representing significant unmet medical needs, gene therapy emerging as a promising approach for genetic neurological conditions, and Voyager's specialized expertise in CNS gene therapy, VYGR offers investors exposure to potentially transformative neurological therapeutics, though gene therapy development in the nervous system carries substantial technical and regulatory risks requiring successful clinical validation.